Quarterly report pursuant to Section 13 or 15(d)

Term Debt (Details)

v3.21.2
Term Debt (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Jul. 16, 2021
Jan. 02, 2020
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 13, 2019
Term Debt (Details) [Line Items]              
Term debt             $ 8,000
Term debt, description   Principal payments will commence July 1, 2022 and continuing for 24 consecutive months thereafter. The Company may prepay all, but not less than all, of the outstanding principal balance of the Term Debt subject to prepayment premium of $240, plus all other sums, if any, that shall have become due and payable.     The Term Debt of $8,000 bears an interest rate equal to the greater of (i) one-half of one percent (0.50%) above the Prime Rate and (ii) five and one-half percent (5.50%). At June 30, 2021, the interest rate was 5.50%. The Term Debt is collateralized by substantially all assets of the Company. Additionally, the Company has pledged 65% of the outstanding capital stock in the Company’s foreign subsidiary, Motus GI Medical Technologies, Ltd., to collateralize the Term Debt.     
Debt issuance costs         $ 50    
Amortized to interest expense     $ 2,000   4,000    
Debt issuance costs       $ 2 $ 4 $ 21  
Effective interest rate on the term debt     5.69%   5.69%    
Bank least         $ 10,000    
Subsequent Event [Member]              
Term Debt (Details) [Line Items]              
Negotiated prepayment premium $ 12,000            
Amount of payment 8,200            
Negotiated prepayment premium $ 220